Fig. 2

Knockdown of SRSF1 suppresses oncogenic roles in vitro and in vivo. a Luminal subtype cell line MCF7 or triple negative breast cancer cell line MDA-MB-231 are transfected with SRSF1 shRNA plasmid (shSRSF1) or control plasmid (pLKO.1). SRSF1 knockdown efficiency is confirmed by western blot and RT-qPCR. b, c Cell proliferation assay and clonogenic survival assay are performed using cells described in (a). d The cell cycle of cells described in (a) is analyzed by flow cytometry and the relative cell population of each cell cycle phase is quantified in the bar graph. e The ration of apoptosis in each group is calculated by flow cytometry. f Measurement of cell migration by wound-healing assays and transwell assays using cells described in (a). g T47D/sh-SRSF1 cells or control T47D/pLKO.1 cells are transplanted to nude mice. Tumors derived from T47D/sh-SRSF1 or control cells are excised and presented. h Volume of tumors are calculated and plotted. i Representative IHC results of SRSF1 and Ki67 in xenografts are presented (200*). *, P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001